Astragaloside IV
(Synonyms: 黄芪皂苷 IV) 目录号 : GN10494Astragaloside IV是黄芪中提取的一种有效成分,可减轻心肌缺血/再灌注损伤,抑制HAdV-3复制,减少HAdV-3诱导的细胞凋亡 。
Cas No.:84687-43-4
Sample solution is provided at 25 µL, 10mM.
Astragaloside IV, an active component isolated from Astragalus membranaceus, can protect the myocardium against ischemia/reperfusion injury and Inhibits HAdV-3 replication and reduces HAdV-3-induced apoptosis [1].
Astragaloside IV (10-160μg/ml; 48h) dose-dependently decreased lncRNA-ATB expression in SMMC-7721 cells. Astragaloside IV (160μg/ml; 48h) down-regulated lncRNA-ATB expression and inhibited HCC cell migration[2].Astragaloside IV (40-100μg/ml; 24h) inhibited the viability and invasive potential of MDA-MB-231 breast cancer cells, suppressed the activation of the mitogen activated protein kinase (MAPK) family members ERK1/2 and JNK, and downregulated matrix metalloproteases (MMP)-2 and -9[3].
Astragaloside IV (12.5, 25, and 50mg/kg; po; 7days) attenuated the neurological deficit in rats with ischemica-reperfusion injury, and reduced cerebral infarction and neuronal apoptosis. Astragaloside IV inhibited the mRNA upregulation of Fas, FasL, Caspase-8, and Bax/Bcl-2[4].After the intervention of Astragaloside IV (20, 40, 80mg/kg; po; 12weeks) the expressions of pSmad3C, pNrf2, HO-1, and NQO1 were increased, and the expressions of TGF-β1, pSmad3L, pSmad2C, pSmad2L, PAI-1 were inhibited[5].
References:
[1]. Shang L, Qu Z, Sun L, Wang Y, Liu F, Wang S, Gao H, Jiang F. Astragaloside IV inhibits adenovirus replication and apoptosis in A549 cells in vitro. J Pharm Pharmacol. 2011 May;63(5):688-94.
[2]. Li Y, Ye Y, Chen H. Astragaloside IV inhibits cell migration and viability of hepatocellular carcinoma cells via suppressing long noncoding RNA ATB. Biomed Pharmacother. 2018 Mar;99:134-141.
[3]. Jiang K, Lu Q, Li Q, Ji Y, Chen W, Xue X. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling. Int Immunopharmacol. 2017 Jan;42:195-202.
[4]. Yin F, Zhou H, Fang Y, Li C, He Y, Yu L, Wan H, Yang J. Astragaloside IV alleviates ischemia reperfusion-induced apoptosis by inhibiting the activation of key factors in death receptor pathway and mitochondrial pathway. J Ethnopharmacol. 2020 Feb 10;248:112319.
[5]. Zhang C, Li L, Hou S, Shi Z, Xu W, Wang Q, He Y, Gong Y, Fang Z, Yang Y. Astragaloside IV inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C/3L and Nrf2/HO-1 pathways. J Ethnopharmacol. 2021 Oct 28;279:114350.
Astragaloside IV是黄芪中提取的一种有效成分,可减轻心肌缺血/再灌注损伤,抑制HAdV-3复制,减少HAdV-3诱导的细胞凋亡[1]。
Astragaloside IV (10-160 μg/ml;48h)呈剂量依赖性地降低SMMC-7721细胞中lncRNA-ATB的表达。Astragaloside IV (160 μg/ml;48h)下调lncRNA-ATB表达抑制肝癌细胞迁移[2]。Astragaloside IV (40-100μg/ml;24h)抑制MDA-MB-231乳腺癌细胞的活力和侵袭潜能,抑制丝裂原活化蛋白激酶(MAPK)家族成员ERK1/2和JNK的活化,下调基质金属蛋白酶(MMP)-2和-9的表达[3]。
Astragaloside IV (12.5、25和50 mg/kg;7 days)可减轻缺血再灌注损伤大鼠的神经功能缺损,减少脑梗死和神经元凋亡。Astragaloside IV抑制Fas、FasL、Caspase-8、Bax/Bcl-2mRNA的上调[4]。Astragaloside IV (20、40、80mg/kg;po;12weeks)干预后,pSmad3C、pNrf2、HO-1、NQO1表达增加,TGF-β1、pSmad3L、pSmad2C、pSmad2L、PAI-1表达抑制[5]。
Cell experiment [1]: | |
Cell lines | SMMC-7721 cells |
Preparation Method | SMMC-7721 cells were treated with Astragaloside IV (10-160μg/ml) for 48hours. |
Reaction Conditions | Astragaloside IV (10-160μg/ml; 48h) |
Applications | Astragaloside IV (10-160μg/ml; 48h)dose-dependently decreased lncRNA-ATB expression in SMMC-7721 cells. |
Animal experiment [2]: | |
Animal models | Cerebral ischemia-reperfusion model |
Preparation Method | Astragaloside IV was administrated to male Sprague-Dawley (SD) rats after transient cerebral ischemia and reperfusion surgery (12.5, 25, and 50mg/kg; once per day; continued for 7 days after surgey). |
Dosage form | Astragaloside IV (12.5, 25, and 50mg/kg; po; 7days) |
Applications | Astragaloside IV (12.5, 25, and 50mg/kg; po; 7days) attenuated the neurological deficit in rats with ischemica-reperfusion injury, and reduced cerebral infarction and neuronal apoptosis. |
References: |
Cas No. | 84687-43-4 | SDF | |
别名 | 黄芪皂苷 IV | ||
化学名 | Astrasieversianin XIV; Astraversianin XIV; Cyclosieversioside F; Cyclosiversioside F | ||
分子式 | C41H68O14 | 分子量 | 784.98 |
溶解度 | DMF: 20 mg/ml,DMSO: 100 mg/mL,DMSO:PBS (pH 7.2) (1:1): 0.5 mg/mL | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.2739 mL | 6.3696 mL | 12.7392 mL |
5 mM | 0.2548 mL | 1.2739 mL | 2.5478 mL |
10 mM | 0.1274 mL | 0.637 mL | 1.2739 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet